Sphere Fluidics, a number one supplier of revolutionary picodroplet-based microfluidics options for practical single cell evaluation and isolation, immediately introduced the launch of Cyto-Mine® Chroma and the opening of its Early Entry Program at SLAS2025 Worldwide Convention and Exhibition in San Diego.
Cyto-Mine Chroma represents the following technology of Sphere Fluidics’ industry-leading Cyto-Mine single-cell evaluation platform. The Early Entry Program supplies a chance to be among the many first to demo the Cyto-Mine Chroma for sooner venture timeline completion and improved outcomes throughout broad purposes, together with antibody discovery, cell line improvement, and rising areas reminiscent of cell remedy. By means of this system, the Firm will collaborate intently with forward-thinking clients to drive innovation and inform the event of future purposes and assays on the platform.
Providing enhanced capabilities, together with multiplexing and better assay flexibility, Cyto-Mine Chroma has been developed to maximise the effectivity and precision of single-cell practical evaluation – enabling tens of tens of millions of cells to be screened in a day. Leveraging a four-color laser and detector system, Cyto-Mine Chroma expands the variety of parameters that may be analyzed for every cell in a single assay. This helps the upcoming launch of the Firm’s first multiplexed assay equipment, facilitating a number of readouts inside a single experiment, optimizing the throughput and precision of cell choice. By accelerating the early number of superior candidate cells for downstream enlargement or additional evaluation, general timelines are decreased from months to weeks, whereas lowering effort and price.
Sphere Fluidics might be showcasing Cyto-Mine Chroma at its sales space (#2744) at SLAS2025. Chief Know-how Officer, Richard Hammond, might be presenting a Options Highlight demonstrating the brand new platform’s capabilities on day two of the convention, Tuesday January twenty eighth, 12:00 – 12:20pm.
The following-generation Cyto-Mine Chroma platform has been designed to remodel single-cell evaluation. We’re excited to unveil this revolutionary platform and its Early Entry Program at SLAS, the premier occasion for lab automation and screening. This launch underscores our dedication to advancing biotechnology. Collaborating intently with key {industry} stakeholders and researchers will permit us to make sure our microfluidic applied sciences meet the evolving wants of the sector, each now and sooner or later.”
Dale Levitzke, CEO, Sphere Fluidics
